Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) An indole compound represented by the formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof;



(I)

wherein ;

R_1 is (c) wherein;

(c) is the group $-(L_1)-R_{11}$; where, $-(L_1)-$ is a divalent linking group of 1 to 8 atoms and where R_{11} is $-(CH_2)_m-R_{12}$;

R_2 is hydrogen, or C1-C4 alkyl;

R_3 is $-(L_3)-$ Z, where $-(L_3)-$ is a divalent linker group selected from a bond or:



or

-CH2-

and Z is a group represented by the formulae,



wherein, X is oxygen or sulfur; and R_a is selected from hydrogen, C_1-C_8 alkyl, aryl, C_1-C_8 alkaryl, C_1-C_8 alkoxy, aralkyl and -CN;

R_4 is the group, -(L_h)-(hydroxyfunctional amide); wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R_5 is selected from hydrogen, a non-interfering substituent, or the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1 to 8;

R_6 and R_7 are selected from hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, and C_2-C_6 alkynyl.

2. (Previously Presented) The compound of claim 1 wherein R_2 is hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, -O-(C_1-C_3 alkyl), -S-(C_1-C_3 alkyl), and C_3-C_4 cycloalkyl.

3. (Cancelled)

4. (Previously Presented) The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(Lh)-, for R_4 is a divalent group selected from,



or



where R_{40}, R_{41}, R_{42}, and R_{43} are each independently selected from hydrogen, C_1-C_8 alkyl.

5. (Cancelled)

6. (Previously Presented) The compound of claim 1 wherein R_5 is the group, -(L_a)-(acidic group) and wherein the (acidic group) is:

-COOH.

7. (Cancelled)
8. (Cancelled)
9. (Cancelled)

10. (Original) The compound of claim 1 wherein for R_3, Z is the group represented by the formula;



and the linking group -(L_3)- is a bond.

11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Original) The compound of claim 1 wherein R4 is the group, -(L_C)-(hydroxyfunctional amide group) and wherein the (hydroxyfunctional amide group) is:



and R^{4a} is independently selected from the group consisting of OH, (C_1-C_6)alkoxy, (C_7-C_{14})alkaryloxy, (C_2-C_8)alkenyloxy, (C_7-C_{14}) aralkyloxy, (C_7-C_{14})aralkenyloxy and aryloxy; and

wherein R^{4b} is independently selected from the group consisting of H, (C_1-C_6)alkyl, arylalkyl, heteroaryl and aryl.

19. (Cancelled)

20. (Previously Presented) A compound selected from the group of:

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(methyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)-*N*-(2-propyl)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-[2-(methyl)propyloxy]acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(methyl)-*N*-(phenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(cyclohexyl)-*N*-(hydroxy)acetamide; and

2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-*N*-(hydroxy)acetamide.

21. (Cancelled)

22. (Original) A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a pharmaceutically acceptable carrier or diluent therefor.

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of Inflammatory Diseases.

26. (Cancelled)

27. (Cancelled)